Galpin/DA/N2 IIIBenv 
TABLE OF CONTENTS 
(Continued) 
3.2 NON-HUMAN PRIMATE MODELS 25 
3.2. 1 CTL Induction 26 
3.2.2 Antibody Induction 26 
3.2.3 Toxicological Assessment 27 
3.2.4 Conclusion 27 
3.3 VECTOR LOCALIZATION 27 
3.4 HUMAN IN VITRO MODEL 29 
3.4.2 Conclusion 32 
4.0 CLINICAL PROTOCOL 53 
5.0 INFORMED CONSENT 83 
6.0 IRB/IBC APPROVAL 92 
7.0 ANSERS TO THE RECOMBINANT DNA ADVISORY COMMITTEE 
(RAC) POINTS TO CONSIDER 96 
APPENDIX A: N2 IIIBENV SEQUENCE 
APPENDIX B: CURRICULUM VITAE 
[862] 
Recombinant DNA Research, Volume 17 
